Abstract
Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Current Pharmaceutical Design
Title: Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Giuseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis and Piero Portincasa
Affiliation:
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Abstract: Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Export Options
About this article
Cite this article as:
Giuseppe Palasciano , Antonio Moschetta , Vincenzo O. Palmieri , Ignazio Grattagliano , Gianluca Iacobellis and Piero Portincasa , Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039652
DOI https://dx.doi.org/10.2174/138161207781039652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pauson-Khand Reaction in the Synthesis of Pharmacologically Active Compounds
Current Organic Chemistry Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Chemical and Pharmacological Significance of 1,4-Dihydropyridines
Current Organic Chemistry Therapeutic Targeting of the Soluble Guanylate Cyclase
Current Medicinal Chemistry Cardiac Consequences of Anti-Inflammatory Drugs in Experimental Models
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry SUBJECT INDEX TO VOLUME 4 Current Organic Chemistry
Current Organic Chemistry Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Hypertension in the Neonatal Period: An Update
Current Hypertension Reviews Mitochondrial Oxidative Stress and Heart Failure ∼Novel Pathophysiological Insight and Treatment Strategies∼
Current Cardiology Reviews A Case of Topiramate-Induced Epistaxis
Current Drug Safety Analysis Toward Innovative Herbal Antibacterial & Antifungal Drugs
Recent Patents on Anti-Infective Drug Discovery Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Triple Antiplatelet Therapy after PCI - Should or Could it be Done?
Cardiovascular & Hematological Disorders-Drug Targets Identifying Structural Features Related to the Biological Activity of a Series of AT1 Antagonists from Fragment-based Drug Design
Protein & Peptide Letters Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart
Current Cardiology Reviews Urinary Albumin to Creatinine Ratio as Potential Biomarker for Cerebral Microvascular Disease
Current Neurovascular Research Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Current Drug Safety Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Current Topics in Medicinal Chemistry Etanercept Improves Cognitive Performance and Increases eNOS and BDNF Expression During Experimental Vascular Dementia in Streptozotocin- induced Diabetes
Current Neurovascular Research